Skip to main content

Table 2 Association analysis of rs3733591 with gout in NZ Māori, EP, WP and Caucasian sample sets and in the FHS cohorta

From: The SLC2A9 nonsynonymous Arg265His variant and gout: evidence for a population-specific effect on severity

  Case genotypesb, n(OR)   Control genotypes, n(OR)      
Sample set CC CT TT C-allele frequency CC CT TT C-allele frequency Genotypic P Allelic P P STRAT Allelic OR, C allele (95% CI)
Māori 101 (0.500) 83 (0.411) 18 (0.089) 0.705 164 (0.500) 138 (0.421) 26 (0.079) 0.710 0.92 0.86 0.93 0.98 (0.74 to 1.28)
EP 119 (0.513) 92 (0.397) 21 (0.091) 0.711 169 (0.506) 139 (0.416) 26 (0.078) 0.714 0.82 0.92 0.80 0.99 (0.76 to 1.28)
WP 39 (0.227) 88 (0.512) 45 (0.262) 0.483 33 (0.239) 57 (0.413) 48 (0.348) 0.446 0.17 0.36 0.65 1.16 (0.84 to 1.59)
NZ Caucasian 217 (0.693) 87 (0.278) 9 (0.029) 0.832 417 (0.656) 196 (0.308) 23 (0.036) 0.810 0.49 0.23 - 1.17 (0.91 to 1.50)
FHS 44 (0.657) 21 (0.313) 2 (0.030) 0.813 3158 (0.670) 1,385 (0.294) 169 (0.036) 0.817 0.92 0.91 - 0.98 (0.63 to 1.51)
ARIC 117 (0.765) 30 (0.196) 6 (0.039) 0.863 4902 (0.704) 1,898 (0.272) 168 (0.024) 0.840 0.07 0.28 - 1.20 (0.86 to 1.67)
  1. aARIC = Atherosclerosis Risk in Communities study; CI = confidence interval; FHS = Framingham Heart Study; OR = odds ratio; EP = Eastern Polynesian; NZ = New Zealand; WP = Western Polynesian PSTRAT = STRAT test for association. bThere was successful genotyping of 202 Māori cases (88%) and 328 Māori controls (96%), 232 EP cases (89%) and 334 EP controls (96%), 172 WP cases (92%) and 138 WP controls (97%) and 313 NZ Caucasian cases (96%) and 636 NZ Caucasian controls (100%).